Fusion Pharmaceuticals In... (FUSN)
NASDAQ: FUSN
· Real-Time Price · USD
21.55
0.03 (0.14%)
At close: Jun 03, 2024, 10:00 PM
Fusion Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 35.68M | 35.7M | 2.21M | 368K | 904K | 1.46M | 1.92M | 2.07M | 2.02M | 1.44M | 846K | 521K | n/a |
Cost of Revenue | 2.7M | 18.21M | 35.46M | 50.97M | 62.11M | 46.23M | 28.63M | 12.08M | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 32.98M | 17.49M | -33.25M | -50.6M | -61.21M | -44.77M | -26.71M | -10M | 2.02M | 1.44M | 846K | 521K | n/a |
Operating Income | -110.24M | -99.23M | -95.37M | -99.79M | -92.36M | -88.03M | -81.17M | -76.88M | -84.86M | -82.02M | -76.06M | -66.86M | -46.91M |
Interest Income | 11.11M | 9.53M | 8.54M | 5.92M | 3.42M | 1.58M | 354K | 164K | 164K | 81K | n/a | n/a | 22K |
Pretax Income | -103.72M | -94.11M | -92.18M | -99.45M | -93.79M | -89.45M | -81.9M | -76.51M | -83.59M | -81.17M | -74.56M | -65.35M | -83.1M |
Net Income | -104.28M | -94.9M | -91.33M | -98.1M | -91.99M | -87.61M | -80.23M | -75.65M | -83.43M | -81.05M | -77.2M | -67.76M | -85.64M |
Selling & General & Admin | 36.74M | 31.2M | 30.52M | 31.13M | 31.16M | 30.6M | 29.99M | 29.72M | 28.58M | 27.1M | 27.4M | 26.04M | 23.38M |
Research & Development | 74.82M | 69.74M | 67.06M | 69.03M | 62.11M | 58.9M | 53.1M | 49.23M | 58.3M | 56.36M | 49.51M | 41.35M | 23.53M |
Other Expenses | 768K | 326K | -354K | -1.9M | -2.4M | -2.25M | -1.51M | -324K | 90K | 138K | 934K | 927K | 927K |
Operating Expenses | 111.56M | 100.94M | 97.58M | 100.16M | 93.27M | 89.5M | 83.08M | 78.95M | 86.89M | 83.45M | 77.05M | 67.48M | 46.96M |
Interest Expense | 5.79M | 5.17M | 5M | 3.86M | 2.58M | 1.44M | 354K | 271K | 368K | 381K | 300K | 273K | 176K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 112.28M | 101.3M | 97.58M | 100.16M | 93.27M | 89.5M | 83.08M | 78.95M | 86.89M | 83.45M | 77.05M | 67.48M | 46.96M |
Income Tax Expense | 561K | 787K | -849K | -1.36M | -1.79M | -1.84M | -1.67M | -861K | -166K | -118K | 2.64M | 2.41M | 2.54M |
Shares Outstanding (Basic) | 83.78M | 73.09M | 69.05M | 66.28M | 53.78M | 44.77M | 43.68M | 43.36M | 43.17M | 43.07M | 43.02M | 42.5M | 41.78M |
Shares Outstanding (Diluted) | 83.78M | 73.09M | 69.05M | 66.28M | 53.78M | 44.77M | 43.68M | 43.36M | 43.17M | 43.07M | 43.02M | 42.5M | 41.78M |
EPS (Basic) | -1.42 | -1.47 | -1.63 | -1.93 | -1.99 | -2 | -1.85 | -1.75 | -1.94 | -1.9 | -1.82 | -1.61 | -19.89 |
EPS (Diluted) | -1.42 | -1.47 | -1.63 | -1.93 | -1.99 | -2 | -1.85 | -1.75 | -1.94 | -1.9 | -1.82 | -1.61 | -19.89 |
EBITDA | -106.6M | -94.18M | -90.06M | -94.23M | -89.5M | -86.74M | -80.51M | -76.28M | -84.32M | -81.56M | -75.75M | -66.59M | -40.58M |
EBIT | -100.57M | -91.59M | -89.83M | -95.59M | -91.26M | -88.06M | -81.6M | -76.29M | -83.22M | -80.78M | -73.93M | -64.75M | -38.01M |
Depreciation & Amortization | 1.43M | 2.85M | 3.12M | 2.98M | 2.86M | 1.29M | 845K | 788K | 726K | 634K | 559K | 477K | 421K |